Therapeutic area intelligence for Transplantation with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 2

Companies

Alkem Labs →

Novartis →

Assets

Tacrolimus →

Recent signals(2)

StrategyAugust 5, 2026

FDA Grants Approval for Tacrolimus ANDA203740 by Alkem Labs

The FDA has granted approval for the ANDA203740 application for Tacrolimus submitted by Alkem Labs.

RegulatoryJuly 21, 2026

FDA Accepts Supplement Application for Sandimmune by Novartis

The FDA has accepted a supplemental application for Sandimmune (cyclosporine) from Novartis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.